OncoMate MSI Dx FDA approval infographic: Keytruda companion diagnostic for MSI-H tumors

OncoMate MSI Dx, Promega Corporation’s PCR-based tumor test, is now FDA-approved as a companion diagnostic for Keytruda (pembrolizumab) in adults and children with advanced microsatellite instability-high (MSI-H) solid tumors, the company announced on November 10, 2026. The approval gives oncologists another FDA-recognised way to confirm which patients qualify for Merck’s tumor-agnostic immunotherapy indication, a use where an estimated one-in-three responders keep their response for years.

Key takeaways on OncoMate MSI Dx

  • The FDA approved Promega’s OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors eligible for pembrolizumab.
  • The test reads five mononucleotide markers (BAT-25, BAT-26, NR-21, NR-24, MONO-27) and compares tumor DNA with the same patient’s normal DNA.
  • A tumor is called MSI-H when two or more of the five markers are unstable.
  • This is the assay’s third US regulatory milestone after a Lynch syndrome screening clearance and a 2025 companion diagnostic approval in endometrial cancer.
  • The test also carries CE marking under the EU IVDR and approval from China’s NMPA for the same Keytruda use.

Why a test matters for a tumor-agnostic drug

Keytruda was the first cancer drug cleared by the FDA on the basis of a biomarker rather than the organ where a tumor started. Its MSI-H/dMMR indication covers unresectable or metastatic solid tumors that have progressed after earlier treatment and have no satisfactory alternative. The 2017 accelerated approval was converted to full approval in March 2023. Because the label requires the biomarker to be identified by an FDA-approved test, every new companion diagnostic widens the set of laboratories that can make that call with regulatory backing.

Microsatellites are short, repeated stretches of DNA. When a cell’s mismatch repair machinery fails, those stretches grow or shrink as the cell divides, and the tumor accumulates many mutations. That mutational load produces abnormal proteins the immune system can recognise, which is why checkpoint inhibitors such as pembrolizumab tend to work well in MSI-H cancers regardless of tissue of origin.

How the OncoMate MSI Dx test works

The assay is a qualitative multiplex PCR test run on formalin-fixed, paraffin-embedded (FFPE) tumor tissue. Laboratories pair each tumor sample with a matched normal sample from the same patient, either normal FFPE tissue or whole blood, so that inherited length differences in the repeats are not mistaken for instability.

FeatureOncoMate MSI Dx detail
MethodQualitative multiplex PCR with fragment analysis
Markers5 mononucleotide repeats: BAT-25, BAT-26, NR-21, NR-24, MONO-27
SamplesFFPE tumor tissue plus matched normal FFPE tissue or whole blood
MSI-H call2 or more of 5 markers unstable
New US use (Nov 2026)Companion diagnostic for pembrolizumab in MSI-H solid tumors
Earlier US usesLynch syndrome triage in colorectal cancer; CDx for pembrolizumab plus lenvatinib in MSS endometrial carcinoma (Nov 2025)
Outside the USCE marked under EU IVDR; NMPA-approved in China for the Keytruda MSI-H use
Sources: Promega announcement as reported by Targeted Oncology and CancerNetwork, November 2026.

According to the FDA premarket approval listing cited by Targeted Oncology, the device sits under PMA P250046 and is linked to the KEYNOTE-028 study. Promega has not published sensitivity or concordance figures in its announcement, so laboratories will need the full labeling for those numbers.

What the pembrolizumab data show in MSI-H tumors

The clinical value of a positive result rests on Merck’s pooled data from KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051, summarised by CancerNetwork. Across 504 patients, the objective response rate was 33.3%, with complete responses in 10.3%. Response rates were similar in colorectal (34%, n=124) and non-colorectal tumors (33%, n=380).

Durability is the striking part. Among 168 responders, 77% were still responding at 12 months and 39% at 36 months, and the median duration of response reached 63.2 months. By our calculation, roughly 65 of the 504 patients (about 13%) held a response for at least three years, which is why correctly identifying MSI-H status carries real weight for treatment decisions.

Limits and open questions

  • Two-sample requirement: a matched normal sample adds a step that immunohistochemistry (IHC) for mismatch repair proteins does not need, though it reduces false calls.
  • No performance data released: the announcement did not include agreement figures versus IHC or next-generation sequencing panels.
  • Not the only option: other FDA-approved companion diagnostics already cover MSI-H selection for pembrolizumab, including sequencing-based tests, so adoption will depend on lab workflow and cost.
  • Late-line use: the Keytruda tumor-agnostic indication applies after progression on prior therapy; earlier-line MSI-H uses in specific cancers have their own labeling.

Market context: companion diagnostics

Tests that decide drug eligibility are a fast-growing segment. Acumen Research and Consulting estimates the global companion diagnostics market at USD 6.3 billion in 2022 and projects USD 20.1 billion by 2032, a 12.5% CAGR. By our calculation that is more than a threefold increase. Acumen reports that PCR held the largest technology share and cancer the largest indication share in 2022, with Asia-Pacific the fastest-growing region. The report page lists an older last-updated date, so treat these figures as indicative.

For Indian oncology centres, the approval is a regulatory signal rather than a local authorisation. Pembrolizumab pricing is shifting in India as biosimilars and price revisions arrive (see our coverage of India’s revision of 543 cancer-medicine brands and Biocon’s biosimilar plans), which could make accurate biomarker selection more important as access widens.

FAQ

What is OncoMate MSI Dx used for?

It detects microsatellite instability in solid tumor tissue. In the US it can now identify MSI-H tumors eligible for Keytruda, flag colorectal cancers for Lynch syndrome follow-up, and select MSS endometrial cancers for Keytruda plus Lenvima.

How many markers does the OncoMate MSI test use?

Five mononucleotide markers. Two or more unstable markers classify the tumor as MSI-H.

Is MSI testing the same as MMR testing?

They measure related things. MMR immunohistochemistry checks whether repair proteins are present; MSI testing measures the DNA consequence of failed repair. Results usually agree, and the Keytruda label accepts either MSI-H or dMMR status.

Is OncoMate MSI Dx available in India?

Promega’s announcement covers the US, the EU (IVDR CE mark) and China. It did not mention Indian regulatory status, so patients should ask their pathology lab which validated MSI or MMR method it uses.

More: FDA approvals on MedGadget.in

Sources: Promega Corporation announcement (November 10, 2026) as reported by Targeted Oncology and CancerNetwork; Merck KEYNOTE pooled data. Market data: Acumen Research and Consulting, Companion Diagnostics Market report. This article is for information only and is not medical or investment advice. Last updated: November 12, 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *